Drugs / chimeric antigen receptor T cell
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03267173 | Jun 2017 → Jun 2019 | malignant pancreatic neoplasm | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04835519 | Apr 2021 → May 2023 | acute myeloid leukemia | Beijing Boren Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04340154 | May 2020 → May 2024 | acute lymphoblastic leukemia | Beijing Boren Hospital | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | chimeric antigen receptor T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04835519 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor engineered T cell immunotherapy” NCT03267173 ↗ |
| Route | Other | “administered by vascular interventional mediated” NCT03267173 ↗ |
| Target | CD22 | “CD22-directed CAR T-cell infusion” PMID 37863088 ↗ Oct 2023 |